DNA Manufacturing Market Size Worth USD 21.82 Billion by 2034 | CAGR: 14.62%

The dna manufacturing market size is expected to reach USD 21.82 billion by 2034, according to a new study by Polaris Market Research. The report “DNA Manufacturing Market Size, Share, Trends, & Industry Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade, By Application, End Use, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

DNA manufacturing, also known as synthetic biology or gene synthesis, is the process of artificially creating DNA molecules in a laboratory. Scientists design and assemble custom DNA sequences using advanced technologies, enabling them to produce genetic material that does not naturally exist or replicate existing sequences for research purposes. DNA manufacturing combines biology, chemistry, and engineering to build precise genetic constructs, creating the way for innovations in medicine, agriculture, and biotechnology.

One of the primary uses of DNA manufacturing is in medical research and drug development. Scientists synthesize genes to study diseases, create vaccines, and develop gene therapies. For instance, synthetic DNA helps produce mRNA vaccines and therapeutics, such as those used against COVID-19, by providing the genetic blueprint for an immune response. Additionally, researchers develop microbes with synthetic DNA to manufacture insulin, antibodies, and other life-saving biologics more efficiently than traditional methods.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/dna-manufacturing-market/request-for-sample

The growing demand for personalized medicine is driving the DNA manufacturing market growth. DNA manufacturing enables scientists to design custom genetic sequences that help create personalized treatments, such as gene therapies for rare genetic disorders or cancer immunotherapies that target specific mutations.

Top of FormDNA Manufacturing Market Report Highlights

• In terms of type, the synthetic DNA segment accounted for a major market share in 2024 due to its widespread applications in therapeutics, diagnostics, and synthetic biology.
• Based on grade, the GMP grade segment held a larger market share in 2024 due to rising demand for clinical-grade DNA used in advanced therapeutic applications such as gene therapy, cell therapy, and DNA-based vaccines.
• In terms of application, the cell & gene therapy segment dominated the revenue market share in 2024. This dominance is attributed to the rapid expansion of clinical and commercial activity in advanced therapeutic platforms.
• Based on end use, the contract research organizations segment is projected to grow at a robust pace in the coming years. CROs offer specialized expertise, scalable manufacturing, and faster turnaround times, making them essential partners for drug development.
• The North America DNA manufacturing market accounted for 47.38% of global revenue share in 2024. This dominance is attributed to advancements in biotechnology, pharmaceuticals, and synthetic biology.
• The DNA manufacturing industry in Asia Pacific is projected to grow at a robust pace in the coming years, owing to expanding biopharmaceutical sectors, increasing R&D investments, and government support for genomics.
• A few global key market players include Catalent; Charles River Laboratories; Danaher; Elegen; Eurofins Genomics; GenScript; Kaneka Corp.; Lonza; ProBio; Thermo Fisher Scientific; Touchlight; VGXI, Inc.; and Wuxi AppTec.

Polaris Market Research has segmented the DNA manufacturing market report on the basis of type, grade, application, end use, and region:

By Type Outlook (Revenue, USD Billion, 2020–2034)

• Plasmid DNA
• Synthetic DNA
  • Gene Synthesis
  • Oligonucleotide Synthesis

By Grade Outlook (Revenue, USD Billion, 2020–2034)

• GMP Grade
• R&D Grade

By Application Outlook (Revenue, USD Billion, 2020–2034)

• Cell & Gene Therapy
• Vaccines
• Oligonucleotide-Based drugs
• Others

By End Use Outlook (Revenue, USD Billion, 2020–2034)

• Pharmaceutical and Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations

By Regional Outlook (Revenue, USD Billion, 2020–2034)

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America